Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Biology » Biotechnology and Genetic Engineering » Bioengineering Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Central Asia: Perspectives and Present Challenges
$160.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to BIOENGINEERING OF HUMAN FETAL TISSUES FOR CLINICAL USE, pp. 133-152
Tell A Friend
 
Tell someone you know about this product.
BIOENGINEERING OF HUMAN FETAL TISSUES FOR CLINICAL USE, pp. 133-152 $100.00
Authors:  Lee Ann Applegate, Nathalie Hirt-Burri, Corinne Scaletta, Jean-François Bauen, Dominique P. Pioletti, Cellular Therapy Unit, Department of Musculoskeletal Medicine (DALO), University Hospital of Lausanne (CHUV-UNIL), Switzerland, and others
Abstract:
Cultured primary fetal cells from one organ donation could possibly meet the exigent
and stringent technical aspects for development of therapeutic products. These cell types
have fewer technological limitations for cellular proliferation capacity (simple culture
conditions) and maintenance of differentiated phenotype, and they also have low
probability for transmission of communicable diseases. Master and Working Cell Banks
(MCB, WCB) can be obtained from one fetal organ donation, permitting multiple tissues
(skin, bone, cartilage, muscle and intervertebral disc) to be processed in short periods of
time with identical methods to assure a stringent tracing of the processes for the
production of standardized therapeutic agents. Clinical use of biologics from embryo and
fetal tissues is relatively new and current legislation and ethics have some differences
between countries to date. In addition, specific cell delivery systems for each tissue type
can be adapted to the clinical application. Since it is the intention that banked primary
fetal cells enhance the prospective treatment of hundreds of thousands of patients with
only one organ donation, it is imperative to show consistency, traceability and safety of
the processes including donor tissue selection, cell banking, cell testing and growth of
cells in out-scaling for the preparation of bio-engineered products for clinical application. 


Available Options:
Version:
This Item Is Currently Unavailable.
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2021

BIOENGINEERING OF HUMAN FETAL TISSUES FOR CLINICAL USE, pp. 133-152